NFL Biosciences

Regulatory Filings • Feb 13, 2024

NFL BIOSCIENCES WILL PRESENT THE RESULTS OF THE PRECESTO CLINICAL STUDY AT THE SRNT CONFERENCE, THE WORLD'S LEADING SCIENTIFIC SOCIETY IN THE FIELD OF NICOTINE AND TOBACCO RESEARCH

NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, has been selected by the SRNT (Society for Research on Nicotine & Tobacco) to present the results of the PRECESTO study at the international conference of the world's leading scientific society in the fight against smoking.

The 2024 edition of the SRNT conference will be held in Edinburgh from March 20 to 23, bringing together the scientific community of European and American experts in the field of nicotine and tobacco. On this occasion, NFL Biosciences will take the floor to present the promising results of the PRECESTO study. Conducted in 2023 on 34 smokers not wishing to quit, the PRECESTO study demonstrated the efficacy of the drug candidate NFL-101 in reducing the satisfaction of smoking compared with a placebo. Detailed results were published on October 5, 2023.

NFL-101 is a nicotine-free tobacco extract derived from a subcutaneous desensitization treatment originally developed by the Pasteur Institute to treat tobacco allergies in tobacco factory workers.

The presentation will take place as NFL Biosciences:

• Recently demonstrated NFL-101's ability to restore normal activity in the brain area associated with the craving to smoke during smoking cessation. This new and disruptive mechanism of action in smoking cessation was highlighted during a molecular imaging study conducted by the French Alternative Energies and Atomic Energy Commission (CEA, "Commissariat à l'Énergie Atomique et aux Énergies Alternatives"), a key player in scientific and technological research, the results of which were published on January 30, 2024 ;
• Is currently carrying out a phase 2b clinical trial, CESTO 2, in nine clinical research centers in France on 318 smokers wishing to quit. Results are expected in July 2024.

About NFL Biosciences

NFL Biosciences is a biopharmaceutical company based in the Montpellier area which develops botanical drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, natural, safer and more effective therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, called NFL-101, is a standardized, nicotine free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who want to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorder.

The shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at www.nflbiosciences.com

Contacts